A phase II study of 6-diazo-5-oxo-L-norleucine (DON, NSC-7365) in advanced large bowel carcinoma.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D001391:Azo Compounds / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy*; D003980:Diazooxonorleucine / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D012004:Rectal Neoplasms / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced
D001391:Azo Compounds; D003980:Diazooxonorleucine